Bile acid supplement

TUDCA (Tauroursodeoxycholic Acid)

The Relyvrio label gives a median Tmax of 4.5 hours for taurursodiol, its name for the bile acid, after a single dose of the combination with sodium phenylbutyrate in fasting healthy subjects; the app lists 2 hours for TUDCA.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

TUDCA (Tauroursodeoxycholic Acid) after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

Elia and colleagues describe tauroursodeoxycholic acid (TUDCA) as "a hydrophilic bile acid that is normally produced endogenously in humans in the liver, by conjugation of taurine to ursodeoxycholic acid (UDCA)".2 The Relyvrio label uses the name taurursodiol for a compound it says "is an ambiphilic bile acid and is the taurine conjugate of ursodiol".1 The Relyvrio label, with an initial US approval year of 2022, covers a fixed combination of sodium phenylbutyrate and taurursodiol, so its results concern the combination and not TUDCA alone.1 A Federal Register notice reports that US approval of the combination was withdrawn after a phase 3 trial "did not meet its prespecified primary and secondary" endpoints.3 DailyMed queries for "taurursodiol" and for "Relyvrio sodium phenylbutyrate taurursodiol" returned no labels on 16 November 2026. The app grades the evidence for TUDCA as strong.

Elia and colleagues write that "Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity".2 Kars and colleagues write that "TUDCA can also act as a chemical chaperone to enhance protein folding and protect cells against ER stress".4 In their trial in obese people, markers of ER stress in muscle or adipose tissue "did not change after treatment with either TUDCA or placebo".4 The authors add that this makes it "unlikely that a reduction in adipocyte ER stress was responsible for the effect on insulin action in this trial".4 They also note that "TUDCA, unlike some other bile acids, is a relatively poor substrate for FXR", and that "The precise cellular mechanisms responsible for the improvement in hepatic insulin sensitivity after TUDCA therapy are not clear".4 The Relyvrio label states that "The mechanism by which RELYVRIO exerts its therapeutic effects in patients with ALS is unknown."1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
95%
Typical dose
250–500 mg/day
Route
Oral
Time to peak
~2 h

The second column holds the app's figures, and the third holds what the sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~6 hThe Relyvrio label gives no taurursodiol half-life, and two PubMed queries on TUDCA pharmacokinetics returned no record whose title reported a human half-life1
Bioavailability95%The Relyvrio label gives no bioavailability for taurursodiol; Kars and colleagues, who gave TUDCA by mouth, wrote that "there is minimal splanchnic escape of bile acid conjugates into the systemic circulation" and "It is likely this difference in route of administration further limited the systemic availability of TUDCA in our subjects" (oral dosing in people against intraperitoneal dosing in mice)1,4
Time to peak~2 hMedian Tmax of 4.5 hours for taurursodiol (0.5 hour for sodium phenylbutyrate) after a single dose of the Relyvrio combination in healthy subjects under fasting conditions1
Protein bindingNot an app figure98% for taurursodiol and 82% for sodium phenylbutyrate in human plasma1
Metabolism and biliary enrichmentNot an app figureThe label lists glyco-ursodiol among major metabolites of taurursodiol and states that no mass balance studies have been conducted in humans; in 24 people with primary biliary cirrhosis, biliary enrichment with ursodeoxycholic acid "ranged from 15% to 48% and was not related with the dose"1,5

The app lists a peak at about 2 hours, and the label figure of 4.5 hours is for the combination product, not for TUDCA given alone. Paganoni and colleagues state that pharmacokinetic data from the CENTAUR trial of the combination "are not presented here because they are still undergoing analysis".6

4

Human studies

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Crosignani and colleagues, Digestive Diseases and Sciences 19965Randomized dose-response trial with three dose groups and no placebo or untreated arm described in the record; funding not stated in the PubMed record524 people with primary biliary cirrhosis5500, 1000 or 1500 mg/day for six months5Serum liver enzymes decreased significantly after the first month at all three doses, with no significant difference among doses, although further reduction over time occurred with 1000 and 1500 mg daily; plasma total and HDL cholesterol significantly decreased at the two higher doses; "Diarrhea was the only side effect"5
Crosignani and colleagues, Hepato-gastroenterology 19987Randomized, placebo-controlled, multicenter; non-U.S. government research support listed in the PubMed record, with no sponsor or author disclosure and no adverse-event data in the PubMed record7150 people with chronic hepatitis (HCV-related)7TUDCA 500 mg or 750 mg/day, or placebo, for 6 months7Aminotransferase levels decreased with TUDCA compared with placebo (p<0.001); the authors write that "Long-term studies with clinically relevant end-points are warranted"7
Ma and colleagues, Medicine 20168Phase III, double-blind, randomized 2:1 against UDCA (no placebo-only arm); sponsored by a Beijing company and a Chinese science programme8199 Chinese adults with primary biliary cholangitis (129 TUDCA, 70 UDCA)8TUDCA or UDCA 250 mg three times daily for 24 weeks8ALP reduction over 25% in 76% on TUDCA and 81% on UDCA (P = 0.453); ALT and GGT fell more with UDCA (P = 0.029, P = 0.027); no serious adverse events8
Heubi and colleagues, Journal of Pediatrics 20029Comparison with a concurrent untreated or placebo group; U.S. government research support listed922 infants given TUDCA and 30 comparison infants after surgery, on total parenteral nutrition9TUDCA 30 mg/kg/day enterally; blood tests followed to 120 days of parenteral nutrition9"There was no difference in peak serum CB, ALT, AP, or BA levels between the TUDCA-treated and control infants"9
Elia and colleagues, European Journal of Neurology 20162Phase II, multicenter, randomized 1:1, placebo-controlled; unrestricted educational grant from Bruschettini234 randomized adults with spinal-onset ALS taking riluzole; 29 analysed2TUDCA 1 g twice daily by mouth or placebo for 54 weeks after a lead-in on riluzole2Responders 13 of 15 (87%) on TUDCA and 6 of 14 (43%) on placebo (P = 0.021); other secondary outcomes did not differ; 1 death on TUDCA and 3 on placebo2
Kars and colleagues, Diabetes 20104Single-blinded, randomized, placebo-controlled; National Institutes of Health grants plus support from Nutricia Research Foundation and Syndexa Pharmaceuticals420 obese adults (8 men, 12 women) with HOMA-IR of 3.0 or more, without diabetes4TUDCA 1,750 mg/day by mouth or placebo for 4 weeks4Hepatic insulin sensitivity index about 30% higher after TUDCA; HOMA-IR decrease not statistically significant; weight, ER stress markers and liver enzymes unchanged4
Paganoni and colleagues, CENTAUR, New England Journal of Medicine 2020 (sodium phenylbutyrate and taurursodiol together, not TUDCA alone)6Multicenter, randomized 2:1, double-blind; funded by Amylyx Pharmaceuticals and others, with four authors affiliated with Amylyx6137 people with definite ALS and symptom onset within 18 months (89 combination, 48 placebo)63 g sodium phenylbutyrate and 1 g taurursodiol once a day for 3 weeks then twice a day, or placebo; 24 weeks6ALSFRS-R change -1.24 against -1.66 points per month (difference 0.42; 95% CI 0.03 to 0.81; P = 0.03); secondary outcomes did not differ significantly; stopped for adverse events 19% against 8%; deaths 5 (6%) against 2 (4%)6
Zucchi and colleagues, EClinicalMedicine 202310Retrospective propensity score-matched cohort from a regional registry; funded by the Emilia-Romagna Region1086 people with ALS who took TUDCA, matched 1:2 to 172 who received usual care only10TUDCA grouped by dose (up to 1000 mg/day or more) and duration (up to 12 months or longer); exposure not assigned10Median survival from onset 49.6 months with TUDCA and 36.2 months in controls; HR 0.56 (95% CI 0.38-0.83; p = 0.0042) at 1000 mg/day or more; 7 (8.1%) stopped for side effects10
TUDCA-ALS, registry entry NCT03800524, Humanitas Mirasole SpA11Phase 3, randomized, quadruple-masked, placebo-controlled; status unknown11337 enrolled (actual count) with ALS taking riluzole11TUDCA 1 g twice daily or placebo for 18 months11The entry lists no results; primary outcome is the number of responders, defined as an improvement of at least 20% in the ALSFRS-R slope11

A registry entry for a phase 1 trial of TUDCA in asthma (NCT03878654, University of Vermont) is listed as terminated, with the reason "IRB protocol violations" and an enrollment count of 11.12

Deeper analysis: Ma and colleagues, TUDCA against UDCA in primary biliary cholangitis (Medicine, 2016)

Ma and colleagues ran a multicenter trial in Chinese adults with primary biliary cholangitis (PBC) who had alkaline phosphatase (ALP) at least twice the upper limit of normal and no previous UDCA treatment.8 The trial used a non-inferiority design: "This test uses positive controlled, noninferiority hypothesis testing".8 Adverse events occurred in 44% of the TUDCA group and 40% of the UDCA group (P = 0.55), and four TUDCA patients (3.1%) had events judged study related: diarrhea in 1 case, pruritus in 2, rash in 1 and dysmenorrhea in 1.8 In the UDCA group 3 patients (4.4%) had study-related events (rash in 1 case and nausea in 2), pruritus or scratch rose from 1.43% to 10.00% in the UDCA group with no change in the TUDCA group (P = 0.023), and the authors conclude that TUDCA "was not inferior to UDCA for this disease".8 The authors list one limitation themselves: "One of the limitations of our study was the relatively short duration of treatment (only 24 weeks)".8 The authors declare no conflicts of interest, and the trial was sponsored by a Beijing company and a Chinese science programme.8

Deeper analysis: Elia and colleagues, TUDCA in ALS (European Journal of Neurology, 2016)

Elia and colleagues, from the Istituto Neurologico Carlo Besta in Milan with centres in Naples and Palermo, enrolled people with spinal-onset ALS who were already taking riluzole.2 The authors call the work "a proof of principle" and say it "was intended as a pilot study".2 The primary outcome was the proportion of responders, defined as people with at least a 15% improvement in the ALSFRS-R slope compared with the lead-in period.2 Of 34 randomized people, "five dropped out before the second visit, i.e. before starting treatment", and four of the 29 analysed died during the study, one on TUDCA and three on placebo.2 At 54 weeks the baseline-adjusted ALSFRS-R score was 23.3 (19.9–26.6) on TUDCA and 16.3 (12.9–19.7) on placebo (P = 0.007).2 The text gives regression slopes of −0.262 for TUDCA and −0.388 for placebo, while the legend of the figure assigns the two values the other way round.2 The survival difference (three deaths on placebo, one on TUDCA) was not significant (P = 0.092), and "post hoc analyses were performed in the evaluation of other outcome measures".2 The report states that "The treatment was well tolerated in all patients", with "Mild diarrhea occurred in two patients treated with TUDCA and in two treated with placebo".2 The authors write that "The findings reported here are to be considered preliminary, particularly in view of the limited sample size", and that the last observation carried forward imputation and the high death rate are possible contributing factors.2 Bruschettini supplied the TUDCA and placebo and gave an unrestricted educational grant, and the authors "declare no financial or other conflicts of interest".2 The registry entry NCT00877604 names the Istituto Neurologico Carlo Besta as lead sponsor.13 The posted results in that entry give the responder counts as 13 of 15 on TUDCA and 6 of 14 on placebo, list its secondary outcomes as not posted, and report no serious or other adverse events in either group, which differs from the four deaths and the mild diarrhea described in the paper.13,2

Deeper analysis: Kars and colleagues, TUDCA and insulin sensitivity in obesity (Diabetes, 2010)

Kars and colleagues at Washington University School of Medicine, St. Louis, randomized 20 obese, insulin-resistant adults without diabetes to TUDCA 1,750 mg/day or placebo for 4 weeks.4 Hepatic insulin sensitivity rose by about 30%, and the rise in muscle glucose disposal above basal during the second clamp stage was "34 ± 23% greater after treatment with TUDCA".4 The authors write that "we did not detect an effect of TUDCA on adipose tissue insulin sensitivity or ER stress".4 HOMA-IR was about 20% lower after TUDCA, but "the decrease in HOMA-IR after TUDCA therapy was not statistically significant".4 The authors state that they "did not obtain liver tissue in our subjects" and that "Additional studies are needed to determine the specific cellular mechanisms responsible for this effect".4 A search of the full text for "adverse" and "side effect" returned no match, so the report gives no adverse event counts in the text read. Funding came from National Institutes of Health grants, the Nutricia Research Foundation and Syndexa Pharmaceuticals; Bruschettini supplied TUDCA and placebo; and one author "is a shareholder and member of the scientific advisory board at Syndexa Pharmaceuticals".4

Deeper analysis: CENTAUR, sodium phenylbutyrate and taurursodiol in ALS (New England Journal of Medicine, 2020)

CENTAUR tested the combination of sodium phenylbutyrate and taurursodiol, so its results do not isolate TUDCA.6 Paganoni and colleagues at Massachusetts General Hospital enrolled 137 people, and the primary outcome was the rate of decline in the ALSFRS-R total score through 24 weeks.6 The primary result was a difference of 0.42 points per month (95% CI 0.03 to 0.81; P = 0.03), and the authors write that "the analysis that corrected for edaravone did not reach statistical significance".6 Serious adverse events were reported in 12% on the combination and 19% on placebo, while discontinuation owing to adverse events was 19% against 8%.6 The authors list as a limitation that "the literature relating to what constitutes a clinically meaningful absolute change in the ALSFRS-R total score is limited", and conclude that "Longer and larger trials are necessary".6 The trial was "Supported by Amylyx Pharmaceuticals, the ALS Finding a Cure Foundation, and the ALS Association", four authors list Amylyx affiliations, and the disclosure forms are published at NEJM.org rather than in the text read.6

Deeper analysis: Zucchi and colleagues, TUDCA and survival in ALS (EClinicalMedicine, 2023)

Zucchi and colleagues used the Emilia Romagna ALS registry in Italy to match 86 people who took TUDCA with 172 who received usual care.10 The primary outcome was survival, "time from onset of symptoms to tracheostomy/death".10 Median overall survival was 49.6 months (95% CI 41.7-93.5) with TUDCA and 36.2 months (95% CI 32.7-41.6) in controls, with a hazard ratio of 0.56 (95% CI 0.38-0.83) at 1000 mg/day or more.10 The authors write that "we could not demonstrate a significant effect of the drug on ALSFRS-R monthly decline".10 Seven people (8.1%) stopped TUDCA because of side effects "primarily gastrointestinal and mild in severity", and 16 (18.6%) discontinued for any reason.10 The authors name "most importantly, immortal time bias" among limitations and write that "Since this was not a controlled study, we cannot rule out additional confounding factors".10 They add that conclusive determinations on outcome measures are not possible given the limited sample size and underpowered analyses, "especially concerning the assessment of adverse effects".10 The funder was the Emilia-Romagna Region, the study states it was performed by public organizations without a private company, and one author reports "advisory board fees from Biogen, Amylix and Italfarmaco".10

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels9 rows
SourceProduct and peopleDose and routeLength
App's figureTUDCA supplement, no population stated250–500 mg/day, oralNot stated
Crosignani 1996524 people with primary biliary cirrhosis in three dose groups500, 1000 or 1500 mg/day by mouth6 months
Ma 20168199 adults with PBC, TUDCA (129) against UDCA (70)250 mg three times daily by mouth (mean 13.69 ± 2.38 mg/kg/day on TUDCA)24 weeks
Elia 2016234 randomized people with ALS taking riluzole, TUDCA against placebo1 g twice daily by mouth (250 mg tablets)54 weeks
Kars 2010420 obese insulin-resistant adults, TUDCA against placebo1,750 mg/day by mouth4 weeks
NCT03800524 (registered plan)11337 people with ALS, TUDCA against placebo, with riluzole1 g twice daily orally18 months
Zucchi 20231086 people with ALS on TUDCA in routine care, 172 matched controlsGrouped at up to 1000 mg/day or moreGrouped at up to 12 months or longer
CENTAUR 2020, combination689 people with ALS on the combination, 48 on placebo1 g taurursodiol with 3 g sodium phenylbutyrate once daily for 3 weeks, then twice daily24 weeks
Relyvrio label, combination1Adults with ALS1 packet (3 g sodium phenylbutyrate and 1 g taurursodiol) daily for the first 3 weeks, then twice dailyInitial 3 weeks, then maintenance

The randomized trials in ALS (Elia) and in obesity (Kars) used 2 g/day and 1,750 mg/day, while the liver trials used 500 to 1500 mg/day (Crosignani 1996), 500 or 750 mg/day (Crosignani 1998) and 250 mg three times daily (Ma), against the app's 250–500 mg/day.2,4,5,7,8 Crosignani and colleagues' dose-response conclusion names "a dose of about 10mg/kg body wt/day of tauroursodeoxycholic acid" for long-term studies in primary biliary cirrhosis.5

In the 24-person dose-response trial in primary biliary cirrhosis, the authors write "Diarrhea was the only side effect".5 In the registry-based cohort, the authors state that gastrointestinal side effects were "reported in almost 20% of TUDCA-exposed patients".10 In CENTAUR, events on the combination were "primarily gastrointestinal (diarrhea, nausea, salivary hypersecretion, and abdominal discomfort)".6 The Relyvrio label lists diarrhea, abdominal pain, nausea and upper respiratory tract infection as the most common adverse reactions (at least 15% and at least 5% greater than placebo) in its 137-person study of the combination.1 The label adds that "Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first 3 weeks of treatment", and that 5 (6%) combination patients and 2 (4%) placebo patients died during the 24-week study.1 For people with disorders that interfere with bile acid circulation, the label states that "there may be an increased risk for worsening diarrhea".1

The app lists no health markers to monitor for TUDCA. In Elia and colleagues' trial, "Laboratory parameters did not change in either treatment group during the course of the study".2 In Kars and colleagues' trial, plasma AST and ALT "did not change after either TUDCA or placebo treatment" in obese adults.4 In the chronic hepatitis trial aminotransferases decreased against placebo, while in Ma and colleagues' comparison in primary biliary cholangitis the reductions in ALP, AST and total bilirubin were similar between TUDCA and UDCA and the reductions in ALT and GGT were greater with UDCA (P = 0.029 and P = 0.027).7,8 The Relyvrio label says "Avoid use of strong inhibitors of BSEP with RELYVRIO" (BSEP is the bile salt export pump) and that if concomitant use of a strong inhibitor such as cyclosporine "is deemed necessary", "monitoring of serum transaminases and bilirubin is recommended".1

A Federal Register notice scheduled for publication on 29 August 2025 states that FDA approved Relyvrio (sodium phenylbutyrate and taurursodiol) for ALS in adults on September 29, 2022.3 The notice states that Amylyx "has voluntarily requested that FDA withdraw" approval and that approval is withdrawn on publication.3 The Relyvrio label, revised 09/2022, states that the product "is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults".1 The Relyvrio patient information names TUDCA as an example of the "taurursodiol products" to mention to a healthcare provider.1 Ma and colleagues write that "TUDCA is available on the market in these countries: Italy, Turkey, and China".8 The text of the WADA 2026 Prohibited List, which "shall come into effect on 1 January 2026", has no match for "bile", "tauro", "ursodeoxy" or "ursodiol" in a search on 16 November 2026.14 A web search on 16 November 2026 indicated that a 2027 list has been published, and that document has not been searched for TUDCA terms.

The sources read give no human half-life or oral bioavailability for TUDCA, so the app's 6 hours and 95% have no figure from the sources beside them. The results of the phase 3 TUDCA-ALS trial were not located; its registry entry gives the status as unknown, last known as active, not recruiting.11 Zucchi and colleagues write that "Additional prospective randomized studies are needed to confirm the efficacy and safety of this drug".10 CENTAUR tested the two ingredients only together, so its results are not results for TUDCA alone.6

What is TUDCA?

TUDCA is tauroursodeoxycholic acid, a hydrophilic bile acid made in the liver by conjugating taurine to ursodeoxycholic acid.2

What is the half-life of TUDCA?

The app lists about 6 hours. The Relyvrio label gives no human half-life figure for taurursodiol, and two PubMed queries on TUDCA pharmacokinetics returned no record whose title reported a human half-life.1

How long does TUDCA take to reach its peak level?

The Relyvrio label gives a median time to maximum concentration of 4.5 hours for taurursodiol after a single dose of the combination in fasting healthy subjects, and the app lists about 2 hours.1

What is the bioavailability of TUDCA?

The app lists 95%, and none of the sources read gives an oral bioavailability figure for TUDCA.1

Is TUDCA approved by the FDA?

The FDA approved the combination Relyvrio (sodium phenylbutyrate and taurursodiol) for ALS in adults on September 29, 2022, and a Federal Register notice scheduled for 29 August 2025 withdrew that approval.3 DailyMed returned no label for taurursodiol on 16 November 2026.

Is TUDCA banned by WADA?

The text of the WADA 2026 Prohibited List has no match for "bile", "tauro", "ursodeoxy" or "ursodiol" in a search on 16 November 2026.14 A web search on 16 November 2026 indicated that a 2027 list has been published, and that document has not been searched for TUDCA terms.

Did TUDCA slow ALS in trials?

In a phase II trial that randomized 34 people with spinal-onset ALS taking riluzole and analysed 29, 13 of 15 on TUDCA and 6 of 14 on placebo were responders on the primary outcome (P = 0.021), the other secondary outcomes did not differ, one person on TUDCA and three on placebo died, the authors write that the findings "are to be considered preliminary, particularly in view of the limited sample size", and the trial was supported by an unrestricted educational grant from Bruschettini.2 The combination of sodium phenylbutyrate and taurursodiol slowed ALSFRS-R decline in the 137-person CENTAUR trial (0.42 points per month; P = 0.03), but secondary outcomes did not differ significantly, the analysis that corrected for edaravone did not reach statistical significance, the trial was supported by Amylyx Pharmaceuticals and others, and the later phase 3 PHOENIX trial "did not meet its prespecified primary and secondary" endpoints.6,3

Did TUDCA lower liver enzymes in trials?

In a 24-person dose-response trial in primary biliary cirrhosis, serum liver enzymes decreased significantly after the first month at 500, 1000 and 1500 mg/day.5 In 150 people with chronic hepatitis, aminotransferase levels decreased against placebo, while in infants on parenteral nutrition peak ALT did not differ between TUDCA-treated and control infants.7,9

What side effects were reported in TUDCA trials?

Diarrhea was the side effect named in the trials of Crosignani (1996) and Elia, and in the registry-based cohort gastrointestinal side effects were reported in almost 20% of TUDCA-exposed patients.5,2,10

Did TUDCA change insulin sensitivity in people?

In a 4-week, single-blinded trial of 20 obese insulin-resistant adults on 1,750 mg/day, the hepatic insulin sensitivity index rose by about 30%, while adipose tissue insulin sensitivity did not change and the decrease in HOMA-IR was not statistically significant; one author is a shareholder and member of the scientific advisory board at Syndexa Pharmaceuticals, which also supported the study.4

12

References

  1. Amylyx Pharmaceuticals. Relyvrio (sodium phenylbutyrate and taurursodiol), for oral suspension. US prescribing information, revised 09/2022 (manufacturer's PDF). Relyvrio label
  2. Elia AE, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 2016. PMID 25664595
  3. US Food and Drug Administration. Amylyx Pharmaceuticals, Inc.; withdrawal of approval of new drug application for Relyvrio (sodium phenylbutyrate and taurursodiol). Federal Register notice, docket FDA-2025-N-2654, scheduled for publication 29 August 2025. Federal Register notice
  4. Kars M, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010. PMID 20522594
  5. Crosignani A, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci 1996. PMID 8674405
  6. Paganoni S, et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 2020. PMID 32877582
  7. Crosignani A, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology 1998. PMID 9840118
  8. Ma H, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) 2016. PMID 27893675
  9. Heubi JE, et al. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr 2002. PMID 12183720
  10. Zucchi E, et al. Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study. EClinicalMedicine 2023. PMID 37842553
  11. ClinicalTrials.gov. NCT03800524. Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS (TUDCA-ALS). Humanitas Mirasole SpA, status verified 2023-07. NCT03800524
  12. ClinicalTrials.gov. NCT03878654. Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma. University of Vermont. NCT03878654
  13. ClinicalTrials.gov. NCT00877604. Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis. Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, status verified 2014-11. NCT00877604
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list